Changes in Toxicity and Effectiveness with Timing of Drug Administration: Implications for Drug Safety

Drug Safety

Volumn 26, Issue 14, 2003, Pages 999-1010

  Ohdo, Shigehiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMITRIPTYLINE; ANTHRACYCLINE; ANTIVIRUS AGENT; CISPLATIN; CORTICOSTEROID; DESIPRAMINE; FLUOROURACIL; FLUVOXAMINE; FOLINIC ACID; HALOPERIDOL; MELATONIN; METHYLPREDNISOLONE; OXALIPLATIN; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ALLERGIC RHINITIS; ARTHRITIS; ASTHMA; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DNA SYNTHESIS; GILLES DE LA TOURETTE SYNDROME; HEART INFARCTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MEAL; MULTICENTER STUDY; NEPHROTOXICITY; NONHUMAN; OVARY CARCINOMA; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; STOMATITIS; STROKE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL CLOCKS; CHRONOTHERAPY; CIRCADIAN RHYTHM; GLUCOCORTICOIDS; HUMANS; INTERFERONS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS;

EID: 0344011544     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326140-00002     Document Type: Review

References (44)

1. Ozdemir V, Shear NH, Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Saf 2001; 24 (2): 75-85
2. Halberg F. Chronobiology. Annu Rev Physiol 1969; 31: 675-725
3. Reinberg A, Halberg F. Circadian chronopharmacology. Annu Rev Pharmacol 1971; 11: 455-92
4. Labrecque G, Belanger PM. Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther 1991; 52: 95-107
5. Haus E, Touittou Y. Chronobiology of development and aging. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin, Heidelberg: Springer-Verlag, 1997: 95-134
6. Smolensky MH, Labrecque G. Chronotherapeutics. Pharmaceutical News 1997; 4: 10-6
7. Duncan WC. Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 1996; 71: 253-312
8. Moore RY, Eichler VB. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res 1972; 42: 201-6
9. Tei H, Okamura H, Shigeyoshi Y, et al. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature 1997; 389: 512-6
10. Chang DC, Reppert SM. The circadian clocks of mice and men. Neuron 2001; 29: 555-8
11. Sakamoto K, Nagase T, Fukui H, et al. Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. J Biol Chem 1998; 273: 27039-42
12. Jin X, Shearman LP, Weaver DR, et al. A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 1999; 96: 57-68
13. Ueyama T, Krout KE, Nguyen XV, et al. Suprachiasmatic nucleus: a central autonomic clock. Nat Neurosci 1999; 2: 1051-3
14. Silver R, LeSauter J, Tresco PA, et al. A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms. Nature 1996; 382: 810-3
15. Mrosovsky N. Problems in interpreting the effects of drugs on circadian rhythms. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin, Heidelberg: Springer-Verlag, 1997: 415-34
16. Moore RY. Chemical neuroanatomy of the mammalian circadian system. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin, Heidelberg: Springer-Verlag, 1997: 79-93
17. Shigeyoshi Y, Taguchi K, Yamamoto S, et al. Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript. Cell 1997; 91: 1043-53
18. Ohdo S, Ogawa N, Nakano S, et al. Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J Pharmacol Exp Ther 1996; 278: 74-81
19. Jones CR, Campbell SS, Zone SE, et al. Familial advanced sleep-phase syndrome: a short-period circadian rhythm variant in humans. Nat Med 1999; 5: 1062-5
20. Lewy AJ. Melatonin as a marker and phase-resetter of circadian rhythms in humans. In: Olcese J, editor. Melatonin after four decades: an assessment of its potentia. New York: Kluwer Academic/Plenum Publishers, 1999: 425-34
21. Akiyama M, Kouzu Y, Takahashi S, et al. Inhibition of light- or glutamate-induced mPer1 expression represses the phase shifts into the mouse circadian locomotor and suprachiasmatic firing rhythms. J Neurosci 1999; 19: 1115-21
22. Horikawa K, Yokota S, Fuji K, et al. Nonphotic entrainment by 5-HT1A/7 receptor agonists accompanied by reduced Per1 and Per2 mRNA levels in the suprachiasmatic nuclei. J Neurosci 2000; 20: 5867-73
23. Ceresa F, Angeli A, Boccuzzi A, et al. Once-a-day neurally stimulated and basal ACTH secretion phases in man and their responses to corticoid inhibition. J Clin Endocrinol Metab 1969; 29: 1074-82
24. Smolensky MH, D'Alozo GE. Progress in the chronotherapy of nocturnal asthma. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin, Heidelberg: Springer-Verlag, 1997: 205-49
25. Reinberg A, Smolensky MH, D'Alonzo GE, et al. Chronobiology and asthma: III. Timing corticotherapy to biological rhythms to optimize treatment goals. J Asthma 1988; 25: 219-48
26. Reinberg A. Chronopharmacology of corticosteroids and ACTH. In: Lemmer B, editor. Chronopharmacology: cellular and biochemical interactions. New York: Marcel Dekker, 1989: 137-78
27. Levy F. Circadian chronotherapy for human cancers. Lancet Oncol 2001; 2: 307-15
28. Levy F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy. Lancet 1997; 350: 681-6
29. Hrushesky WJM. Circadian timing of cancer chemotherapy. Science 1985; 228: 73-5
30. Ohdo S, Makinosumi T, Ishizaki T, et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther 1997; 283: 1383-8
31. Takane H, Ohdo S, Yamada T, et al. Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice. J Pharmacol Exp Ther 2000; 294: 746-52
32. Dagan Y. Circadian rhythm sleep disorders (CRSD) in psychiatry: a review. Isr J Psychiatry Relat Sci 2002; 39 (1): 19-27
33. Wirz-Justice A, Cajochen C, Nussbaum P. A schizophrenic patient with an arrhythmic circadian rest-activity cycle. Psychiatry Res 1997; 73: 83-90
34. 34. Dagan Y. Sleep wake schedule disorders as a possible side effect of CNS medications [abstract]. Chronobiol Int 1999; 16: 25
35. Wirz-Justice A, Werth E, Savaskan E, et al. Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Dis Assoc Disord 2000 Oct-Dec; 14: 212-215
36. Ayalon L, Hermesh H, Dagan Y. Case study of circadian rhythm sleep disorder following haloperidol treatment: reversal by risperidone and melatonin. Chronobiol Int 2002; 19 (5): 947-59
37. Hermesh H, Lemberg H, Abadi J, et al. Circadian rhythm sleep disorders (CRSD) as a possible side effect of fluvoxamine. CNS Spectr 2001; 6: 511-3
38. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47
39. Janssen HL, Brouwer JT, van der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21: 241-3
40. Bocci V. Administration of interferon at night may increase its therapeutic index. Cancer Drug Deliv 1985; 2: 313-8
41. Ohdo S, Koyanagi S, Suyama H, et al. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med 2001; 7: 356-60
42. Koyanagi S, Ohdo S. Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism. Mol Pharmacol 2002; 62: 1393-9
43. Hunter CA, Gabriel KE, Radzanowski T, et al. Type I interferons enhance production of IFN-γ by NK cells. Immunol Lett 1997; 59: 1-5
44. Lundkvist GB, Robertson B, Mhlanga JD, et al. Expression of an oscillating interferon-γ receptor in the suprachiasmatic nuclei. Neuroreport 1998; 9: 1059-63